Researchers launch study to unravel mysteries of rare immune disorder sHLH
NCT ID NCT06339177
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This study aims to understand why some adults develop secondary hemophagocytic lymphohistiocytosis (sHLH), a serious immune condition causing fevers and organ damage. Researchers will follow 300 participants for up to 3 years, collecting blood samples and medical data to identify immune patterns and triggers. No new treatments are given, but findings may lead to better diagnosis and future therapies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward better diagnostic tools and potential targets for future treatments for secondary HLH.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly provide new therapies, and results may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Apr 2031
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult participants with active secondary HLH by meeting any published criteria. Hemophagocytic lymphohistiocytosis (HLH) represents a clinical condition of persistent, dysregulated immune activation with unrelenting fevers, hyperferritinemia, and cytopenias, which lead to multiorgan failure and death.
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Aged 18 years or older. * Established diagnosis of sHLH defined by meeting any published criteria, per Table 1: * Meeting the HLH-2004 criteria. * HScore of \>168. For those without a bone marrow biopsy to evaluate for hemophagocytosis (worth 35 points in the criteria), HScore\>134 will be used. * For those with underlying rheumatologic disease: meeting the 2016 American College of Rheumatology criteria for macrophage activation syndrome. * Agree to storage and sharing of study data and biospecimens for future research use. Table 1: Published Criteria for HLH HLH-2004 Criteria: Molecular diagnosis of HLH OR At least 5 of 8 below criteria: * Fever (\>38.4 Degrees Celcius) * Splenomegaly * Cytopenias affecting \>=2 of 3 lineages: Hgb \<9 g/dL, platelets \<10\^5/microliter, neutrophils \<10\^6/microliter * Hypertriglyceridemia (\>256 mg/dL) and/or fibrinogen \<1.5 g/L * Hemophagocytosis on biopsy * Serum ferritin \>=500 ng/mL * Increased serum sCD25 (\>2400 U/mL) * Low or absent NK cell activity HScore: Known immunosuppression: 0 (no) or 18 (yes) Temperature (degrees, Celsius): 0 (\<38.4), 33 (38.4-39.4), 49 (\>39.4) Organomegaly: 0 (no), 23 (liver/spleen), 38 (both) Number of cytopenias: 0 (1 lines), 24 (2 lines), 34 (3 lines) Ferritin (ng/mL): 0 (\<2000), 35 (2000-6000), 50 (\>6000) Triglycerides (mg/dL): 0 (\<1.5), 44 (1.5-4), 66 (\>4) Fibrinogen (g/L): 0 (\>2.5), 30 (\<2.5) AST (IU/mL): 0 (\<30), 19 (\>30) Hemophagocytosis: 0 (no) or 35 (yes) Cutoff value=169 ACR 2016-MAS Criteria: A febrile patient with known or suspected sJIA is classified as having macrophage activation syndrome if the following criteria are met: Ferritin \>684 ng/mL AND any 2 of the following: * Platelets \<=181,000/microliter * AST \>48 IU/mL * Triglycerides \>156 mg/dL * Fibrinogen \<=3.6 g/L Abbreviations: ACR, American College of Rheumatology; AST, aspartate transaminase; Hgb, hemoglobin; HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; NK, natural killer, sJIA, systemic juvenile idiopathic arthritis. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Currently pregnant. * Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperinflammatory syndromes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
-
University of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15261, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare immune disease: drug combo shows promise in small study
- Gentler transplant shows promise for kids with blood diseases
- New drug aims to calm dangerous immune storms in Still's and lupus patients
- Small study aims to unlock immune chaos in sepsis patients
- New hope for HLH patients: targeted drug tested in clinical trial
- Can an arthritis drug tame deadly dengue inflammation?